These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 25311757)

  • 1. Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program.
    Bruno S; Bollani S; Zignego AL; Pascasio JM; Magni C; Ciancio A; Caremani M; Mangia A; Marenco S; Piovesan S; Chemello L; Babudieri S; Moretti A; Gea F; Colletta C; Perez-Alvarez R; Forns X; Larrubia JR; Arenas J; Crespo J; Calvaruso V; Ceccherini Silberstein F; Maisonneuve P; Craxì A; Calleja JL;
    J Viral Hepat; 2015 May; 22(5):469-80. PubMed ID: 25311757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trials.
    Vierling JM; Zeuzem S; Poordad F; Bronowicki JP; Manns MP; Bacon BR; Esteban R; Flamm SL; Kwo PY; Pedicone LD; Deng W; Dutko FJ; DiNubile MJ; Koury KJ; Helmond FA; Wahl J; Bruno S
    J Hepatol; 2014 Aug; 61(2):200-9. PubMed ID: 24747798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.
    Bernabucci V; Ciancio A; Petta S; Karampatou A; Turco L; Strona S; Critelli R; Todesca P; Cerami C; Sagnelli C; Rizzetto M; Cammà C; Villa E
    World J Gastroenterol; 2014 Nov; 20(44):16726-33. PubMed ID: 25469044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected Patients.
    Yang CC; Tsai WL; Su WW; Huang CF; Cheng PN; Lo CC; Tseng KC; Mo LR; Wang CH; Hsu SJ; Lai HC; Su CW; Liu CJ; Peng CY; Yu ML
    PLoS One; 2015; 10(9):e0137852. PubMed ID: 26368130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response.
    Vierling JM; Davis M; Flamm S; Gordon SC; Lawitz E; Yoshida EM; Galati J; Luketic V; McCone J; Jacobson I; Marcellin P; Muir AJ; Poordad F; Pedicone LD; Albrecht J; Brass C; Howe AY; Colvard LY; Helmond FA; Deng W; Treitel M; Wahl J; Bronowicki JP
    J Hepatol; 2014 Apr; 60(4):748-56. PubMed ID: 24362076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis.
    Bruno S; Vierling JM; Esteban R; Nyberg LM; Tanno H; Goodman Z; Poordad F; Bacon B; Gottesdiener K; Pedicone LD; Albrecht JK; Brass CA; Thompson S; Burroughs MH
    J Hepatol; 2013 Mar; 58(3):479-87. PubMed ID: 23183529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients.
    Braun DL; Rauch A; Aouri M; Durisch N; Eberhard N; Anagnostopoulos A; Ledergerber B; Müllhaupt B; Metzner KJ; Decosterd L; Böni J; Weber R; Fehr J;
    PLoS One; 2015; 10(7):e0133028. PubMed ID: 26176696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of treatment week eight response & sustained virologic response in patients treated with boceprevir plus peginterferon alfa and ribavirin.
    Thompson A; Devine S; Kattan M; Muir A
    PLoS One; 2014; 9(8):e103370. PubMed ID: 25084272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
    Hézode C; Fontaine H; Dorival C; Zoulim F; Larrey D; Canva V; De Ledinghen V; Poynard T; Samuel D; Bourliere M; Alric L; Raabe JJ; Zarski JP; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Chazouilleres O; Abergel A; Guyader D; Metivier S; Tran A; Di Martino V; Causse X; Dao T; Lucidarme D; Portal I; Cacoub P; Gournay J; Grando-Lemaire V; Hillon P; Attali P; Fontanges T; Rosa I; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP;
    Gastroenterology; 2014 Jul; 147(1):132-142.e4. PubMed ID: 24704719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome.
    Cento V; Di Paolo D; Di Carlo D; Micheli V; Tontodonati M; De Leonardis F; Aragri M; Antonucci FP; Di Maio VC; Mancon A; Lenci I; Manunta A; Taliani G; Di Biagio A; Nicolini LA; Nosotti L; Sarrecchia C; Siciliano M; Landonio S; Pellicelli A; Gasbarrini A; Vecchiet J; Magni CF; Babudieri S; Mura MS; Andreoni M; Parruti G; Rizzardini G; Angelico M; Perno CF; Ceccherini-Silberstein F
    Dig Liver Dis; 2015 Feb; 47(2):157-63. PubMed ID: 25544656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin.
    Jacobson IM; Marcellin P; Zeuzem S; Sulkowski MS; Esteban R; Poordad F; Bruno S; Burroughs MH; Pedicone LD; Boparai N; Deng W; DiNubile MJ; Gottesdiener KM; Brass CA; Albrecht JK; Bronowicki JP
    Hepatology; 2012 Aug; 56(2):567-75. PubMed ID: 22619063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfected patients.
    Miailhes P; Gilbert C; Lacombe K; Arends JE; Puoti M; Rockstroh JK; Sogni P; Fontaine H; Rosenthal E; Winnock M; Loko MA; Wittkop L; Dabis F; Salmon D;
    Liver Int; 2015 Sep; 35(9):2090-9. PubMed ID: 25650873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis.
    Salmerón J; Vinaixa C; Berenguer R; Pascasio JM; Sánchez Ruano JJ; Serra MÁ; Gila A; Diago M; Romero-Gómez M; Navarro JM; Testillano M; Fernández C; Espinosa D; Carmona I; Pons JA; Jorquera F; Rodriguez FJ; Pérez R; Montero JL; Granados R; Fernández M; Martín AB; Muñoz de Rueda P; Quiles R;
    World J Gastroenterol; 2015 Aug; 21(30):9163-74. PubMed ID: 26290644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Lead-in period and week 8 as predictive tools for response to boceprevir therapy: a retrospective study of Spanish real clinical practice].
    Crespo J; Berenguer M; Pérez F; Fernández I; González O; Bárcena R; Buti M; López J; Calleja JL;
    Gastroenterol Hepatol; 2015 Nov; 38(9):517-24. PubMed ID: 25976446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
    Aherfi S; Solas C; Motte A; Moreau J; Borentain P; Mokhtari S; Botta-Fridlund D; Dhiver C; Portal I; Ruiz JM; Ravaux I; Bregigeon S; Poizot-Martin I; Stein A; Gérolami R; Brouqui P; Tamalet C; Colson P
    J Med Virol; 2014 Nov; 86(11):1868-76. PubMed ID: 25052594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis.
    Calleja JL; Pascasio JM; Ruiz-Antorán B; Gea F; Bárcena R; Larrubia JR; Pérez-Álvarez R; Sousa JM; Romero-Gómez M; Solá R; de la Revilla J; Crespo J; Navarro JM; Arenas JI; Delgado M; Fernández-Rodríguez CM; Planas R; Buti M; Forns X;
    Liver Int; 2015 Jan; 35(1):90-100. PubMed ID: 25113158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.
    Hézode C; Fontaine H; Dorival C; Larrey D; Zoulim F; Canva V; de Ledinghen V; Poynard T; Samuel D; Bourlière M; Zarski JP; Raabe JJ; Alric L; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Métivier S; Tran A; Serfaty L; Abergel A; Causse X; Di Martino V; Guyader D; Lucidarme D; Grando-Lemaire V; Hillon P; Feray C; Dao T; Cacoub P; Rosa I; Attali P; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP;
    J Hepatol; 2013 Sep; 59(3):434-41. PubMed ID: 23669289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Boceprevir early-access for advanced-fibrosis/cirrhosis in Asia-Pacific hepatitis C virus genotype 1 non-responders/relapsers.
    Sukeepaisarnjaroen W; Pham T; Tanwandee T; Nazareth S; Galhenage S; Mollison L; Totten L; Wigg A; Altus R; Colman A; Morales B; Mason S; Jones T; Leembruggen N; Fragomelli V; Sendall C; Guan R; Sutedja D; Tan SS; Dan YY; Lee YM; Luman W; Teo EK; Than YM; Piratvisuth T; Lim SG
    World J Gastroenterol; 2015 Jul; 21(28):8660-9. PubMed ID: 26229408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A real life boceprevir use in treatment-experienced HCV genotype 1 patients with advanced fibrosis.
    Gheorghe L; Iacob S; Simionov I; Caruntu F; Motoc A; Arama V; Preotescu L; Stefan I; Goldis A; Brisc C; Rugina S; Rednic N
    J Gastrointestin Liver Dis; 2014 Mar; 23(1):45-50. PubMed ID: 24689096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic hepatitis C genotype 1 treatment roadmap for resource constrained settings.
    Lim SG
    World J Gastroenterol; 2015 Feb; 21(6):1972-81. PubMed ID: 25684966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.